Newsroom

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains the renewal of its Marketing Authorization (MA) for Sibnayal® (fixed combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) in the European Union. The European Medicines Agency (EMA) ha...

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), société pharmaceutique spécialisée dans le développement et la commercialisation de traitements innovants pour les personnes souffrant de maladies rénales rares, annonce le renouvellement de l’Autorisation de Mise sur le Marché (AMM) de Sibnayal® (combinaison fixe de citrate et de bicarbonate de potassium) dans le traitement de l’Acidose Tubulaire Rénale distale (ATRd) dans l’Union Européenne. L'Age...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces today that the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has emitted a favorable opinion on the Paediatric Investigation Plan (PIP) for AEF0217 (EMA/PE/0000243385; IRIS: 0075800000532) in the t...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News : Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements des maladies cérébrales et périphériques impliquant le récepteur CB1, annonce aujourd’hui que le Comité pédiatrique (PDCO) de l’EMA a émis un avis favorable au consensus sur le Plan d’Investigation Pédiatrique (PIP) de AEF0217 (EMA/PE/0000243385 ; IRIS : 0075800000532) dans le t...

OXFORD, England--(BUSINESS WIRE)--Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company’s first IVD device registered in the UK and Europe. The CE and UKCA certification confirms that GridION™ Dx meets stringent international standards for quality, safety, and performance, positioning Oxford Nanopore for future adoption in regulated clinical markets and reflecting its long-term commitment to sequencing-based diagnostics. “Being C...

WOODBRIDGE, Conn.--(BUSINESS WIRE)--ChemWerth, a global leader in generic active pharmaceutical ingredient development and supply, welcomes Chandrakanth Reddy to support its growth....

AUSTIN, Texas--(BUSINESS WIRE)--Kubota dealerships ranked highest in the 2026 Compact Tractor Internet Lead Effectiveness study; half of tractor inquiries go unanswered industrywide...

STOCKHOLM--(BUSINESS WIRE)--At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solu...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ: MAT) unveiled today its first-ever autistic Barbie doll created with guidance from the autistic community to represent common ways autistic people may experience, process, and communicate about the world around them. This doll invites more children to see themselves represented in Barbie. Developed for more than 18 months in partnership with ASAN, a non-profit disability rights organization run by and for autistic people that advocates...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ : MAT) a dévoilé aujourd'hui sa toute première poupée Barbie autiste, créée avec l'aide de la communauté autiste afin de représenter les façons courantes dont les personnes autistes peuvent percevoir, traiter et communiquer sur le monde qui les entoure. Cette poupée invite davantage d'enfants à se reconnaître dans Barbie. Développée pendant plus de 18 mois en partenariat avec ASAN, une organisation à but non lucratif dédiée aux droits de...